SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services
11.12.2024 15:05:00 CET | Business Wire | Press release
Streamlined Organization Lays Foundation for Company Rebrand
SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industries, today announced the launch of a brand unification initiative. This strategic move brings together the expertise and capabilities of several industry-respected organizations under the unified SK pharmteco brand.
This initiative builds on the legacies of SK biotek, SK biotek Ireland, Center for Breakthrough Medicines, Yposkesi, AMPAC Fine Chemicals, and AMPAC Analytical to create a Contract Development and Manufacturing Organization (CDMO) powerhouse. While these individual brands will continue to operate, they will now be known collectively as SK pharmteco, symbolizing a new era of innovation and growth.
“By uniting under the SK pharmteco banner, we create a stronger, more streamlined organization that delivers a seamless experience for our clients,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Our combined capabilities encompass many services, from early-stage development to commercial manufacturing and state-of-the-art analytical testing. This comprehensive offering empowers us to support our partners throughout the entire drug development lifecycle and, ultimately, quickly provide life-changing therapies to those who need it most.”
Building upon this brand unification, SK pharmteco will unveil a comprehensive rebranding initiative. This transformation will encompass a recently launched new website with a fresh URL, www.skpharmteco.com, along with modern and cohesive visual imagery, and updated email addresses to reflect the unified SK pharmteco brand identity.
“Our rebrand marks a pivotal moment for SK pharmteco, aligning our identity with our mission to deliver transformative medicines to patients and our commitment to providing exceptional service to our customers,” said Liza Rivera, SK pharmteco’s Vice President of Marketing & Communications, who is leading the branding efforts. “Additionally, it reflects our dedication to innovation, collaboration, and excellence as a trusted partner.”
The unified SK pharmteco boasts a robust global footprint with facilities strategically located across North America, Europe, and Asia. This extensive network ensures efficient project management and facilitates close collaboration with clients worldwide.
The company’s expanded service portfolio encompasses:
- Process development and manufacture of small molecules (APIs intermediates and registered starting materials)
- Cell and Gene Therapy (CGT) development and manufacturing
- Analytical development and testing services
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211426371/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 14:30:00 CEST | Press release
Public equities have re-emerged as the primary destination for incremental capital Private markets remain a strategic pillar of family office portfolios Artificial intelligence is moving from experimentation toward implementation Cross-border complexity is rising as families become increasingly international Leadership succession and next-generation preparedness are now immediate priorities rather than distant considerations Watch Citi Wealth’s Global Family Office leadership discuss the report’s findings here. Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Tod
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 14:30:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
Manhattan Associates Announces Editions™ for its Industry-Leading Solutions, Making Them Accessible at Every Stage of Growth22.9.2026 14:30:00 CEST | Press release
New offering gives commercial and growing enterprises the right-sized path to start their journey with Manhattan, and scale on the same platform as their business grows Manhattan Associates (NASDAQ: MANH), the global leader in supply chain commerce with unmatched AI capabilities, today announced the commercial launch of Editions for Manhattan Active® solutions. Editions provide a new way for companies of all sizes and across industries to partner with Manhattan. They are designed to help growing organizations make a durable, long-term technology decision from the start. As complexity increases, customers can unlock additional capabilities on the same platform, rather than starting over. Built for ActiveWarehouse™, ActiveTransportation™, ActiveStore™ and ActiveOrder™, on Manhattan’s award-winning ActivePlatform™, there are three Editions available: Essentials, Enterprise and Enterprise Premier. Regardless of the Edition selected for each solution, companies gain access to the power of a
Elydan Acquieres Radpol Pipes in Poland Expanding Its Offering to Accelerate the Decarbonization of Europe's Energy Infrastructure22.9.2026 14:24:00 CEST | Press release
ELYDAN Group, specialist in water and energy network solutions, announces the acquisition of Radpol Pipes, a Polish industrial company specializing in the manufacture of pre-insulated piping systems for district heating and cooling networks. The acquisition expands Elydan’s capabilities in low-carbon energy infrastructure. The Group is entering a new phase of its European development with more than €250 million in revenue and 600 employees across 7 European countries. Expanding in Europe market driven by decarbonization and energy sovereignty “With Radpol Pipes, we are adding the technological expertise needed to cover the full range of district heating and cooling networks. This acquisition reflects a very concrete ambition: to provide our customers with the most comprehensive solutions to accelerate the decarbonization of infrastructure and contribute to Europe’s energy sovereignty. It is also a key milestone in our Momentum 2030 strategy, reinforcing our ambition to build a leading
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 14:01:00 CEST | Press release
14 ADX-listed companies will present their growth strategies and equity stories to international investors The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom